Sheryl Treichel

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Jason Chesney, Antoni Ribas, Georgina V. Long et al. · Journal of Clinical Oncology · 2022 · 284 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

Reinhard Dummer, David Gyorki, John Hyngstrom et al. · Nature Medicine · 2021 · 148 citations

Medicine, Oncology, Surgery +14

Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus—a large‐scale multicentre pilot study¹

Esther Müller–Godeffroy, Sheryl Treichel, Verena M. Wagner · Diabetic Medicine · 2009 · 134 citations

Medicine, Child Health, Pediatrics +17

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

A. Ribas, Jason Chesney, Georgina V. Long et al. · Annals of Oncology · 2021 · 57 citations

Pharmacy, Oncology, Pharmacotherapy +14

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

Robert Hans Ingemar Andtbacka, Reinhard Dummer, David Gyorki et al. · Journal of Clinical Oncology · 2018 · 41 citations

Medicine, Oncology, Surgery +17